Matinas Biopharma Holdings Inc (MTNB)

[john26632]

From the most recent 10Q:

Assuming the Company obtains FDA approval for one or more of its product candidates, which the Company does not expect to receive until 2023 at the earliest, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

AMRN is a much better buy, Dilution is in the rear view mirror and FDA approval by years end.